PROLIA (denosumab) by Amgen is rank ligand blocking activity [moa]. Approved for postmenopausal women with osteoporosis at high risk for fracture, defined, multiple risk factors for fracture and 3 more indications. First approved in 2010.
Drug data last refreshed 13h ago
PROLIA (denosumab) is a monoclonal antibody that blocks RANK ligand, a key mediator of bone resorption. It is administered via subcutaneous injection and is indicated for osteoporosis and other bone loss conditions. The drug works by inhibiting osteoclast formation and survival, thereby reducing bone resorption and increasing bone mineral density. PROLIA represents a non-hormonal, biologic approach to bone health management and has become a cornerstone therapy in the osteoporosis treatment landscape since its 2010 FDA approval.
RANK Ligand Blocking Activity
RANK Ligand Inhibitor
Worked on PROLIA at Amgen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAmgen is hiring 9 roles related to this product
$673M Medicare spend — this is a commercially significant brand
PROLIA supports 930 currently open job positions across commercial, medical, and operations functions, reflecting the scale of the established franchise. Key roles include brand managers, field sales representatives, medical science liaisons, market access specialists, and regional directors managing a mature, high-volume product. Success in PROLIA roles requires strong understanding of biosimilar differentiation, formulary navigation, patient access solutions, and healthcare economics as the competitive landscape intensifies.